Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820092 · ClinicalTrials.gov registry record · Phase 1
Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers
A Phase 1 study of Edema, sponsored by Celtic Pharma Development Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT00820092 is a Phase 1 study of Edema that has completed, run by Celtic Pharma Development Services. The registered enrollment target is 38 participants, below the 462-participant average among 13 other Edema trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00820092, a Phase 1 study of Edema, has completed, sponsored by Celtic Pharma Development Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
1. To investigate the safety and tolerability of Xerecept during and following a 24-hour intravenous administration to healthy Japanese to healthy Japanese and Caucasian subjects 2. To compare the PK profile of hCRF during and following a 24-hour intravenous Xerecept administration between healthy Japanese and Caucasian subjects
Conditions Studied
Interventions
- DRUG Xerecept 1.0
- DRUG Xerecept 2.0
- DRUG Xerecept 3.0
Study Locations (1)
California
- West Coast Clinical Trials - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00820092
The ClinicalTrials.gov registry entry for NCT00820092 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 13 other Edema trials with a reported enrollment target (92% lower). The listed sponsor is Celtic Pharma Development Services, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Edema appearing as the primary indexed condition, and to 3 interventions - of which Xerecept 1.0 is the first listed.
NCT00820092 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00820092 about?
NCT00820092 is a clinical study titled "Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers". 1. To investigate the safety and tolerability of Xerecept during and following a 24-hour intravenous administration to healthy Japanese to healthy Japanese and Caucasian subjects 2. To compare the PK profile of hCRF during and following a 24-hour intravenous Xerecept administration between healthy J...
What is the current status of trial NCT00820092?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2008-12. Estimated completion is 2009-04.
What conditions does trial NCT00820092 study?
This clinical trial studies the following conditions: Edema.
What interventions are being tested in trial NCT00820092?
The interventions under investigation include: Xerecept 1.0 (DRUG), Xerecept 2.0 (DRUG), Xerecept 3.0 (DRUG).
Who is sponsoring clinical trial NCT00820092?
This trial is sponsored by Celtic Pharma Development Services, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00820092 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)
RECRUITING · NA
-
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
RECRUITING
-
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
RECRUITING · NA
-
Diuretic Tuner Clinical Decision Support
RECRUITING · NA
-
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
RECRUITING
-
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.